Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
About this item
Full title
Author / Creator
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
Arsenic trioxide (ATO) is an effective cancer therapeutic drug for acute promyelocytic leukemia and has potential anticancer activity against a wide range of solid tumors. ATO exerts its effect mainly through elevated oxidative stress, but the exact molecular mechanism remains elusive. The thioredoxin (Trx) system comprising NADPH, thioredoxin redu...
Alternative Titles
Full title
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_201373525
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_201373525
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.0701549104
